Seniors are now the fastest-growing demographic of cannabis consumers. This same pattern may play out as psychedelic drugs are legalized and commercialized.
Red Light Holland Engages Radixmotion to Develop an Innovative Virtual Reality Shopping Experience for Dutch Smart Shops and e-Commerce Platforms
Red Light Holland is adding an education-based VR tool to its e-commerce platform.
Why Getting In Early Is Especially Important With Psychedelics Stocks
The time is ripe for entry into psychedelics stocks.
Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute
Mydecine's recent acquisition, NeuroPharm Inc, is about to commence clinical trials using psilocybin to treat PTSD.
PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.
PharmaDrug (CAN:BUZZ / US:LMLLF) and Red Light Holland (CAN:TRIP) have entered into a share exchange agreement.
Why Psychedelics Microdosing Applications Have The Inside Track On Commercialization
Microdose-based psychedelic drug therapies have several advantages , ranging from R&D and drug licensing all the way through to drug commercialization and market penetration. It all adds up to greater profit potential.
Novamind Announces Closing of Oversubscribed Private Placement
NovaMind closes on a CAD$4.4 million financing, upsized from the original CAD$3.0 million placement.
Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc
This release confirms Mydecine's June 10th announcement of the acquisition of NeuroPharm Inc.
Champignon Provides Corporate Update
Champignon provides an update on its current trading halt and other corporate matters.
Psychedelic Drugs: the $16 TRILLION Opportunity?
A 2018 report estimates that mental health issues could cost the global economy $16 trillion between now and 2030. Psychedelic drugs are needed to mitigate those costs.
MagicMed Industries Files First Psychedelic Derivative Patent
MagicMed files with the USPTO with respect to its "broad portfolio of novel psilocybin molecular derivatives, the Psybrary™".
Pharmadrug Inc. Provides Update on Debt Restructuring
PharmaDrug is restructuring approximately $1 million in debt in the form of convertible debentures.
